These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1706591)

  • 1. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.
    Trudel M; Stott EJ; Taylor G; Oth D; Mercier G; Nadon F; Séguin C; Simard C; Lacroix M
    Arch Virol; 1991; 117(1-2):59-71. PubMed ID: 1706591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
    Arbiza J; Taylor G; López JA; Furze J; Wyld S; Whyte P; Stott EJ; Wertz G; Sullender W; Trudel M
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2225-34. PubMed ID: 1383404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus.
    Nicholas JA; Mitchell MA; Levely ME; Rubino KL; Kinner JH; Harn NK; Smith CW
    J Virol; 1988 Dec; 62(12):4465-73. PubMed ID: 2460636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.
    Taylor G; Stott EJ; Furze J; Ford J; Sopp P
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2217-23. PubMed ID: 1383403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus.
    Hsu SC; Chargelegue D; Obeid OE; Steward MW
    J Gen Virol; 1999 Jun; 80 ( Pt 6)():1401-1405. PubMed ID: 10374957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
    Murphy BR; Walsh EE
    J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
    Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
    Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.
    Chargelegue D; Obeid OE; Hsu SC; Shaw MD; Denbury AN; Taylor G; Steward MW
    J Virol; 1998 Mar; 72(3):2040-6. PubMed ID: 9499058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide mimics of a conformationally constrained protective epitopes of respiratory syncytial virus fusion protein.
    Chargelegue D; Obeid OE; Shaw DM; Denbury AN; Hobby P; Hsu SC; Steward MW
    Immunol Lett; 1997 Jun; 57(1-3):15-7. PubMed ID: 9232419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.
    López JA; Andreu D; Carreño C; Whyte P; Taylor G; Melero JA
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2567-77. PubMed ID: 7506298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
    J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus.
    Bourgeois C; Corvaisier C; Bour JB; Kohli E; Pothier P
    J Gen Virol; 1991 May; 72 ( Pt 5)():1051-8. PubMed ID: 2033389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.
    Lounsbach GR; Bourgeois C; West WH; Robinson JW; Carter MJ; Toms GL
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2559-65. PubMed ID: 7506297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
    Murphy BR; Olmsted RA; Collins PL; Chanock RM; Prince GA
    J Virol; 1988 Oct; 62(10):3907-10. PubMed ID: 3047432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactive and group-specific immune responses to a neutralizing epitope of the human respiratory syncytial virus fusion protein.
    Corvaisier C; Bourgeois C; Pothier P
    Arch Virol; 1997; 142(6):1073-86. PubMed ID: 9228999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.